Upgrade to SI Premium - Free Trial

Amarin Corp. (AMRN) Tops Q1 EPS by 6c, Revenues Beat

May 1, 2019 5:51 AM

Amarin Corp. (NASDAQ: AMRN) reported Q1 EPS of ($0.05), $0.06 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $73.3 million versus the consensus estimate of $67.3 million.

Key Amarin achievements in Q1 2019 include:

“Initial reaction from the medical community to REDUCE-IT results has been very encouraging, including the updated guidelines from the ADA. Our expanded sales team is off to a good start and we are optimistic regarding the potential results of pharmacoeconomic analysis expected later this year,” commented John Thero, Amarin’s president and chief executive officer. “We remain very early in the process of introducing Vascepa to healthcare professionals and we remain limited in what we can say about Vascepa, particularly to consumers, until the label for Vascepa is expanded. We are confident in the robust results of the REDUCE-IT study and we look forward to interacting with regulatory authorities in their review of these Vascepa clinical results in conjunction with the expanded labeling we seek for Vascepa.”

For earnings history and earnings-related data on Amarin Corp. (AMRN) click here.


Corporate News Earnings Management Comments

Next Articles